New aflibercept injection pre-filled syringe in EUMay 9, 2020
The European Medicines Agency (EMA) has granted approval for the new aflibercept (Eylea) injection pre-filled syringe.
This new presentation provides ophthalmologists with a more efficient and convenient way to administer the drug across all approved indications, as the pre-filled syringe requires fewer steps to prepare compared to the intravitreal injection procedure of the existing vial, Bayer said.
Bayer has recently published the results from the phase IV ALTAIR study, which confirmed the effectiveness of aflibercept with treat and extend (T&E) dosing regimens in wet age-related macular degeneration (wet AMD).
The results demonstrated a considerable injection burden reduction, since up to 60% patients were able to achieve injection intervals of three-months (12-week interval) or more whilst more than 40% achieved injection intervals of four-months (16-week interval). Aflibercept is the only approved anti-VEGF to successfully extend to 16-week treatment intervals in clinical trials.